Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia, which suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups.
A. Kalogeropoulos, A. M. Rashid, S. Anker et al.· Kidney360· 0 citations
INTRODUCTION
Once-weekly (OW) semaglutide has shown renal benefits in clinical trials for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This study compared clinical outcomes between OW semaglutide and selected oral glucose-lowering medications in real-world settings.
METHODS
Adults with T2D an...
James Amamoo, Yan Wang, Hong-Jiao Liu et al.· Advances in Therapy· 0 citations
INTRODUCTION
Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-control...
M. Weir, S. Bhaduri, Keung Lee et al.· Kidney International· 1 citation
Resistant hypertension, defined as blood pressure above target despite treatment with at least three antihypertensive agents (including a diuretic) or controlled blood pressure requiring four or more medications, affects over 140 million individuals globally and confers increased risks of heart failure, stroke, and chr...
M. S. Khan, Muhammad Sameer Arshad, Michael E. Hall et al.· American Society of Nephrolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.